Logo
x

Search

Subscribe Now

BMS

BMS’ Opdivo Qvantig SC Injection Secures the US FDA’s Approval for Solid Tumor Opdivo Indications

BMS’ Opdivo Qvantig SC Injection Secures the US FDA’s Approval for Solid Tumor Opdivo Indications

  • December 30, 2024
BMS Reports Topline Data from Two Pivotal P-III Studies of Sotyktu (Deucravacitinib) for Treating Psoriatic Arthritis (PsA)

BMS Reports Topline Data from Two Pivotal P-III Studies of Sotyktu (Deucravacitinib) for Treating Psoriatic Arthritis (PsA)

  • December 25, 2024
BMS Reports the EC’s Approval of Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as a 1L Treatment of MSI-H/dMMR Metastatic Colorectal Cancer (mCRC)

BMS Reports the EC’s Approval of Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as a 1L Treatment of MSI-H/dMMR Metastatic Colorectal...

  • December 24, 2024
BMS’ Opdivo + Yervoy Receives the CHMP’s Positive Opinion as a 1L Treatment of Metastatic Colorectal Cancer

BMS’ Opdivo + Yervoy Receives the CHMP’s Positive Opinion as a 1L Treatment of Metastatic Colorectal Cancer

  • November 18, 2024
BMS’ Repotrectinib Gains the CHMP’s Positive Opinion to Treat Advanced ROS1+ NSCLC and NTRK+ Solid Tumors

BMS’ Repotrectinib Gains the CHMP’s Positive Opinion to Treat Advanced ROS1+ NSCLC and NTRK+ Solid Tumors

  • November 15, 2024
PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

  • October 4, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.